Novo Nordisk Cuts Price of Wegovy by Up to 37% in India
The Danish drug-maker has reduced the Indian retail price of its obesity treatment Wegovy (semaglutide) by up to 37%, aiming to broaden access as competition in the weight-loss drug category intensifies.

👨‍⚕️ From a Doctor’s Perspective

• Patient access improvement: Lowering the price means more patients struggling with obesity may now be able to afford this therapy.

• Clinical protocols matter: With greater uptake, the responsibility rises to monitor patients closely—ensuring appropriate selection, managing side-effects, and combining with lifestyle interventions.

• Health system impact: This change might push other pharma companies to adjust pricing, which could reshape how we think about treatment affordability in metabolic diseases.

• Caution remains: Price reduction is good, but we must ensure that prescribing is evidence-based, not driven by marketing, and that long-term outcomes are diligently tracked.